Cargando…

Interaction between sex and neurofilament light chain on brain structure and clinical severity in Huntington’s disease

Female Huntington’s disease (HD) patients have consistently shown a faster clinical worsening than male, but the underlying mechanisms responsible for this observation remain unknown. Here, we describe how sex modifies the impact of neurodegeneration on brain atrophy and clinical severity in HD. Cer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampedro, Frederic, Martinez‐Horta, Saul, Pérez‐Pérez, Jesús, Perez‐Gonzalez, Rocio, Horta‐Barba, Andrea, Campolongo, Antonia, Aracil‐Bolaños, Ignacio, Gomez‐Anson, Beatriz, Kulisevsky, Jaume
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670315/ https://www.ncbi.nlm.nih.gov/pubmed/34761569 http://dx.doi.org/10.1002/acn3.51460

Ejemplares similares

Structural brain correlates of dementia in Huntington’s disease
por: Martinez-Horta, Saul, et al.
Publicado: (2020)

Measuring the functional impact of cognitive impairment in Huntington’s disease
por: Horta-Barba, Andrea, et al.
Publicado: (2022)

The Free and Cued Selective Reminding Test in Parkinson's Disease Mild Cognitive Impairment: Discriminative Accuracy and Neural Correlates
por: Horta-Barba, Andrea, et al.
Publicado: (2020)

Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia
por: Sampedro, Frederic, et al.
Publicado: (2020)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
por: Kulisevsky, Jaime, et al.
Publicado: (2022)

Early Gray Matter Volume Loss in MAPT H1H1 de Novo PD Patients: A Possible Association With Cognitive Decline
por: Sampedro, Frederic, et al.
Publicado: (2018)

The impact of dopaminergic treatment over cognitive networks in Parkinson's disease: Stemming the tide?
por: Aracil‐Bolaños, Ignacio, et al.
Publicado: (2021)

White matter cortico-striatal tracts predict apathy subtypes in Huntington's disease
por: De Paepe, Audrey E., et al.
Publicado: (2019)

Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease
por: Garcia-Gorro, Clara, et al.
Publicado: (2019)

Measuring cognitive impairment and monitoring cognitive decline in Huntington’s disease: a comparison of assessment instruments
por: Horta-Barba, Andrea, et al.
Publicado: (2023)

Genotype–Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities
por: Ruiz-Barrio, Iñigo, et al.
Publicado: (2022)

Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity
por: Marín-Lahoz, Juan, et al.
Publicado: (2018)

Lamin B1 and nuclear morphology in peripheral cells as new potential biomarkers to follow treatment response in Huntington's disease
por: Garcia‐Forn, Marta, et al.
Publicado: (2023)

The Evolution of Neurofilament Light Chain in Multiple Sclerosis
por: Ferreira-Atuesta, Carolina, et al.
Publicado: (2021)

Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie
por: Betancor, Marina, et al.
Publicado: (2022)

Telling true from false: cannabis users show increased susceptibility to false memories
por: Riba, J, et al.
Publicado: (2015)

Alterations in Cerebral White Matter and Neuropsychology in Patients with Cirrhosis and Falls
por: Gómez-Ansón, Beatriz, et al.
Publicado: (2015)

Effects of a Green Oat Herb Extract on Cognitive Performance and Neurophysiological Activity: A Randomized Double-Blind Placebo-Controlled Study
por: Martinez-Horta, Saul, et al.
Publicado: (2021)

Association Between Insulin‐Like Growth Factor‐1 and Social Cognition in Huntington's Disease
por: Gil‐Polo, Cecilia, et al.
Publicado: (2022)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
por: Niemelä, Valter, et al.
Publicado: (2017)

The relationship between lifestyle and serum neurofilament light protein in Huntington’s disease
por: Cruickshank, Travis, et al.
Publicado: (2020)

Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments
por: Ackerley, Steven, et al.
Publicado: (2003)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

4472 Plasma Neurofilament Light as a Biomarker for Pediatric Patients with Huntington’s Disease
por: Schultz, Jordan L
Publicado: (2020)

Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children
por: Byrne, Lauren M., et al.
Publicado: (2022)

Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)

Editorial: Neuroimaging of Cognitive and Neuropsychiatric Symptoms in Movement Disorders
por: Sampedro, Frederic, et al.
Publicado: (2022)

Plasma neurofilament light in Huntington’s disease: A marker for disease onset, but not symptom progression
por: Parkin, Georgia M., et al.
Publicado: (2021)

Neurofilament light-associated connectivity in young-adult Huntington’s disease is related to neuronal genes
por: McColgan, Peter, et al.
Publicado: (2022)

Neurofilament light chain in the vitreous humor of the eye
por: Subramanian, Manju L., et al.
Publicado: (2020)

Blood Neurofilament Light Chain: The Neurologist’s Troponin?
por: Thebault, Simon, et al.
Publicado: (2020)

Kynurenines and Neurofilament Light Chain in Multiple Sclerosis
por: Pukoli, Dániel, et al.
Publicado: (2021)

Neurofilament light chain concentration in an aging population
por: Ladang, Aurélie, et al.
Publicado: (2022)

Blood neurofilament light chain in Parkinson’s disease
por: Buhmann, Carsten, et al.
Publicado: (2023)

Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels
por: Kušnierová, Pavlína, et al.
Publicado: (2019)

CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
por: Reyes, Saúl, et al.
Publicado: (2020)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
por: Varhaug, Kristin N., et al.
Publicado: (2019)

Neurofilament Light Chain as A Biomarker for Brain Metastases
por: Winther-Larsen, Anne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g20o0ur5av14s19scplrieqjor